Bristol Myers Squibb’s CAR-T Liso Cell wins FDA nod with long delay
After the regulatory delays and manufacturing problems investors of Bristol Myers Squibb missed the lucrative Celgene conditional value right, the meticulous CAR-T drug liso-cell finally got an FDA…
